Nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-19 and is reviewed periodically as new material appears.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
== Antibiotic resistance == Drug resistance in bacteria is an example of an outcome of natural selection. When a drug is used on a species of bacteria, those that cannot resist die and do not produce offspring, while those that survive potentially pass on the resistance gene to the next generation (vertical gene transmission). The resistance gene can also be passed on to one bacterium by another of a different species (horizontal gene transmission). Because of this, the drug resistance increases over generations. For example, in hospitals, environments are created where pathogens such as C. difficile have developed a resistance to antibiotics. Antibiotic resistance is made worse by the misuse of antibiotics. Antibiotic resistance is encouraged when antibiotics are used to treat non-bacterial diseases, and when antibiotics are not used for the prescribed amount of time or in the prescribed dose. Antibiotic resistance may arise out of standing genetic variation in a population or de novo mutations in the population. Either pathway could lead to antibiotic resistance, which may be a form of evolutionary rescue.
The yeast has a negative effect on the bacteria that normally produce antibiotics to kill the parasite, so may affect the ants' health by allowing the parasite to spread. A different yeast species is grown by fungus-growing ants of the genus Cyphomyrmex. Certain strains of some species of yeasts produce proteins called yeast killer toxins that allow them to eliminate competing strains. (See main article on killer yeast.) This can cause problems for winemaking but could potentially also be used to advantage by using killer toxin-producing strains to make the wine. Yeast killer toxins may also have medical applications in treating yeast infections (see "Pathogenic yeasts" section below). Marine yeasts, defined as the yeasts that are isolated from marine environments, are able to grow better on a medium prepared using seawater rather than freshwater. The first marine yeasts were isolated by Bernhard Fischer in 1894 from the Atlantic Ocean, and those were identified as Torula sp. and Mycoderma sp. Following this discovery, various other marine yeasts have been isolated from around the world from different sources, including seawater, seaweeds, marine fish and mammals. Among these isolates, some marine yeasts originated from terrestrial habitats (grouped as facultative marine yeast), which were brought to and survived in marine environments. The other marine yeasts were grouped as obligate or indigenous marine yeasts, which are confined to marine habitats. However, no sufficient evidence has been found to explain the indispensability of seawater for obligate marine yeasts.
Ibotenic acid, or ibotenate, also known as premuscimol or as (S)-2-amino-2-(3-hydroxyisoxazol-5-yl)acetic acid, is a naturally occurring α-amino acid found in certain Amanita mushrooms such as Amanita muscaria. It acts primarily as a potent glutamate receptor agonist and produces neurological effects. The compound is used as a brain-lesioning agent in scientific research. Ibotenic acid is a conformationally-restricted analogue of the excitatory neurotransmitter glutamate which acts as a non-selective agonist of glutamate receptors, strongly activating NMDA, group I and II metabotropic glutamate receptors, and weakly activating AMPA and kainate receptors. Taken systemically, it is a prodrug of muscimol, broken down by the liver into this more stable compound, which acts as a potent GABAA and GABAA-ρ receptor agonist. Although the compound's psychoactive effects are not well-understood, some researchers speculate that ibotenic acid itself may have stimulant-like properties. Ibotenic acid is biosynthesized from glutamic acid by hydroxylation catalyzed by an Fe(II)/2-oxoglutarate-dependent oxygenase, with subsequent conversion steps carried out by enzymes encoded within a linked biosynthetic gene cluster. Ibotenic acid is commonly used in research to create site-specific hippocampal brain lesions in rats, allowing for task relearning due to its interaction with glutamate receptors, and is favored over other agents for its selectivity and long-term stability in saline solution.
=== Other programs === LLNL supports capabilities in a broad range of scientific and technical disciplines, applying capabilities to existing programs and developing new science and technologies to meet future national needs.
Ranged combat is first-person, with character points assigned to the firearms skill determining the shot's accuracy and how long it takes to target an opponent. Melee combat is third-person, with access to weapons such as katanas and sledgehammers for melee combat, or pistols, crossbows, and flamethrowers for firearm combat. If a player sneaks up on an opponent, they can perform an instant kill; weapons provide unique instant kill animations. The player can block attacks manually or automatically by leaving their character idle. They can use stealth in missions by sneaking past guards and security cameras, picking locks, and hacking computers to locate alternative routes. Each clan has specific Disciplines, which can be used in combat and to create approaches to quests. Although some powers overlap clans, no two clans share the same three Disciplines. More physical vampires can enhance themselves to become fast and lethal killers or summon spirit allies to attack their foes; others can mentally dominate their targets to force their cooperation or render themselves invisible to hide from detection; and others can boil their opponent's blood from afar. The ability Blood Buff (which temporarily upgrades physical abilities) is common to all vampires. Several abilities can be active at the same time. Blood is a primary currency in Bloodlines, used to activate Disciplines and abilities.
Sources: en.wikipedia.org
== Production == Most 131I production is from neutron irradiation of a natural tellurium target in a nuclear reactor. Irradiation of natural tellurium produces almost entirely 131I as the only radionuclide with a half-life longer than hours (and shorter than millions of years), since lighter isotopes of tellurium become heavier stable isotopes, or else stable antimony or iodine. However, the heaviest naturally occurring tellurium nuclide, 130Te (34% of natural tellurium) absorbs a neutron to become tellurium-131, which beta decays with a half-life of 25 minutes to 131I. A tellurium compound can be irradiated while bound as an oxide to an ion exchange column, with evolved 131I then eluted into an alkaline solution. More commonly, powdered elemental tellurium is irradiated and then 131I separated from it by dry distillation of the iodine, which has a far higher vapor pressure. The element is then dissolved in a mildly alkaline solution in the standard manner, to produce 131I as iodide and hypoiodate (which is soon reduced to iodide). 131I is a fission product with a yield of 2.878% from uranium-235, and can be released in nuclear weapons tests and nuclear accidents. However, the short half-life means it is not present in significant quantities in cooled spent nuclear fuel, unlike iodine-129 whose half-life is nearly a billion times that of 131I. It is discharged to the atmosphere in small quantities by some nuclear power plants.
experienced by the crack due to the applied loading. Fast fracture will occur when the stress intensity exceeds the fracture toughness of the material. The prediction of crack growth is at the heart of the damage tolerance mechanical design discipline.
The US Food and Drug Administration (FDA) and Health Canada have approved pregabalin (an anticonvulsant) and duloxetine (a serotonin–norepinephrine reuptake inhibitor) for the management of fibromyalgia. The FDA also approved milnacipran (another serotonin–norepinephrine reuptake inhibitor), but the European Medicines Agency refused marketing authority. In 2025, the US Food and Drug Administration (FDA) approved TNX-102 SL, as Tonmya, for the management of fibromyalgia, making it the first new FDA-approved fibromyalgia therapy in over 15 years. (NDA 219428) A 2024 overview of Cochrane reviews concluded that the FDA-approved medications: duloxetine, milnacipran, or pregabalin were the only ones with evidence of efficacy. About 10% of patients with moderate or severe pain using them experienced a reduction of at least 50% in their pain. Another 2024 review found that currently available pharmacological options appeared to be limited in efficacy for FM. Fibromyalgia is often treated or managed with meds including amitriptyline, citalopram, duloxetine, fluoxetine, paroxetine and sertraline. The length of time that medications take to be effective at reducing symptoms can vary. Any potential benefits from the antidepressant amitriptyline may take up to three months to take effect, and it may take between three and six months for duloxetine, milnacipran, and pregabalin to be effective at improving symptoms. Some medications have the potential to cause withdrawal symptoms when stopping, so gradual discontinuation may be warranted, particularly for antidepressants and pregabalin.
Jameson's mamba (Dendroaspis jamesoni) is known to be quite aggressive and defensive. The average venom yield per bite for this species is 80 mg, but some specimens may yield as much as 120 mg in a single bite. The SC LD50 for this species according to Brown (1973) is 1.0 mg/kg, while the IV LD50 is 0.8 mg/kg. Envenomation by Jameson's mamba can be deadly in as little as 30 to 120 minutes after being bitten, if proper medical treatment is not attained. The mortality rate of untreated bites is not exactly known, but it's said to be very high (>80%).
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.